Clinical trial
A Phase 1b/2 Study of AZD0120, a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Refractory Systemic Lupus Erythematosus (SLE)
NCT06897930 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b/2 Study of AZD0120, a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Refractory Systemic Lupus Erythematosus (SLE)
- Lead sponsor
- AstraZeneca
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- April 21, 2025
- Completion date
- May 1, 2029
- Enrollment
- 150 (estimated)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.